CO6141479A2 - Proceso para producir poxvirus y composiciones de poxvirus - Google Patents

Proceso para producir poxvirus y composiciones de poxvirus

Info

Publication number
CO6141479A2
CO6141479A2 CO08133446A CO08133446A CO6141479A2 CO 6141479 A2 CO6141479 A2 CO 6141479A2 CO 08133446 A CO08133446 A CO 08133446A CO 08133446 A CO08133446 A CO 08133446A CO 6141479 A2 CO6141479 A2 CO 6141479A2
Authority
CO
Colombia
Prior art keywords
vaccinia virus
recombinant modified
modified ankara
ankara vaccinia
stage
Prior art date
Application number
CO08133446A
Other languages
English (en)
Inventor
Daniel Malarme
Yves Cordier
Claude Sene
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6141479(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of CO6141479A2 publication Critical patent/CO6141479A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1.- Un virus vaccinia Ankara modificado recombinante, en donde dicho virus vaccinia Ankara modificado recombinante es un EEV sin especificidad de infección objetivada. 2.- El virus vaccinia Ankara modificado recombinante de acuerdo con la reivindicación 1, en donde dicho virus vaccinia Ankara modificado recombinante comprende una secuencia exógena que codifica una molécula que tiene directa o indirectamente una función cítotóxica. 3.- El virus vaccinia Ankara modificado recombinante de acuerdo con la reivindicación 2, en donde dicha secuencia exógena es un gen suicida. 4.- El virus vaccinia Ankara modificado recombinante de acuerdo con la reivindicación 1, en donde dicho virus vaccinia Ankara modificado recombinante comprende una secuencia exógena que codifica un antígeno Asociado a Tumor (TAA). 5.- El virus vaccinia Ankara modificado recombinante de acuerdo con la reivindicación 1, en donde en donde dicho virus vaccinia Ankara modificado recombinante comprende una secuencia exógena que codifica un antígeno. 6.- El virus vaccinia Ankara modificado recombinante de acuerdo con la reivindicación 5, en donde dicho antígeno se deriva de un virus. 7.- El virus vaccinia Ankara modificado recombinante de acuerdo con una cualquiera de las reivindicaciones 1 a 6, en donde dicho virus vaccinia Ankara modificado recombinante comprende los elementos necesarios para la expresión de la secuencia exógena. 8.- Un proceso para producir un poxvirus intacto, un poxvirus atenuado y/o un poxvirus recombinante sin especificidad de infección objetivada que comprende las etapas de: a) preparar un cultivo de células de empaque b) infectar dicho cultivo celular c) cultivar dichas células infectadas durante un periodo de tiempo apropiado d) recuperar las partículas poxvíricas producidas a partir del sobrenadante de cultivo y/o las células de empaque e) una etapa de aclaración de la mezcla obtenida a partir de la etapa d), permitiendo el retiro de los residuos celulares, en donde dicha etapa de aclaración es una etapa de filtración profunda. f) una etapa de concentración, en donde dicha etapa de concentración es una etapa de microfiltración, y g) una etapa de diafiltración y en donde dicho proceso está libre de productos animales. 9.- El proceso de acuerdo con la reivindicación 8, en donde dicha célula de empaque es un CEF.
CO08133446A 2006-06-20 2008-12-16 Proceso para producir poxvirus y composiciones de poxvirus CO6141479A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360027 2006-06-20
US86145206P 2006-11-29 2006-11-29

Publications (1)

Publication Number Publication Date
CO6141479A2 true CO6141479A2 (es) 2010-03-19

Family

ID=40770647

Family Applications (1)

Application Number Title Priority Date Filing Date
CO08133446A CO6141479A2 (es) 2006-06-20 2008-12-16 Proceso para producir poxvirus y composiciones de poxvirus

Country Status (22)

Country Link
US (5) US8058049B2 (es)
EP (2) EP2029756B1 (es)
JP (1) JP5456464B2 (es)
KR (1) KR101082296B1 (es)
CN (1) CN101460627B (es)
AU (1) AU2007263280B2 (es)
BR (1) BRPI0712158B8 (es)
CA (1) CA2656259C (es)
CO (1) CO6141479A2 (es)
CR (1) CR10528A (es)
DK (2) DK2029756T3 (es)
ES (2) ES2671230T3 (es)
HK (1) HK1125405A1 (es)
HU (2) HUE030533T2 (es)
IL (1) IL194978A (es)
MA (1) MA30580B1 (es)
MX (2) MX2008015166A (es)
NO (1) NO20084855L (es)
NZ (1) NZ573437A (es)
RU (3) RU2551982C2 (es)
WO (1) WO2007147528A1 (es)
ZA (1) ZA200810658B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2029756T3 (en) * 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
US8716016B2 (en) * 2008-04-23 2014-05-06 Board Of Trustees Of Michigan State University Immortal avian cell line and methods of use
EP2387414A1 (en) 2009-01-13 2011-11-23 Transgene SA Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
EP2427547A1 (en) * 2009-05-08 2012-03-14 GlaxoSmithKline Biologicals S.A. Method for producing virus from cell culture involving homogenization
EP2429579A1 (en) 2009-05-12 2012-03-21 Transgene SA Immortalized avian cell lines and use thereof
TW201109440A (en) 2009-07-21 2011-03-16 Transgene Sa Enzymatic composition for the digestion of chicken embryos
CN102313803A (zh) * 2011-06-21 2012-01-11 贵州大学 山羊痘正向间接血凝诊断试剂及其制备方法和检测方法
KR101370620B1 (ko) * 2011-08-05 2014-03-06 한국생명공학연구원 다람쥐폭스바이러스를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
CA2954841A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
CN104147145B (zh) * 2014-07-31 2017-01-11 许峰 一种预防和治疗羊痘的药剂
WO2016087457A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
PL3402802T3 (pl) 2016-01-08 2023-06-05 Geovax, Inc. Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
AU2018270375A1 (en) 2017-05-15 2019-10-31 Bavarian Nordic A/S Stable virus-containing composition
JP2020519666A (ja) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定性のウイルス含有組成物
JP7334124B2 (ja) * 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020007010A (es) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
US20220347244A1 (en) * 2018-01-19 2022-11-03 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
CA3124773A1 (en) 2018-12-28 2020-07-02 Transgene M2-defective poxvirus
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
IL296250A (en) 2020-03-12 2022-11-01 Bavarian Nordic As The compounds that improve the stability of the smallpox virus
WO2022013221A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
WO2023128672A1 (ko) * 2021-12-29 2023-07-06 재단법인 아산사회복지재단 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023238106A1 (en) 2022-06-10 2023-12-14 Transgene Recombinant virus expressing interleukin-12
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024023740A1 (en) 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB9001641D0 (en) 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
GB9208402D0 (en) 1992-04-16 1992-06-03 Devro Ltd Rotatable linking and hanging device
JPH08511423A (ja) 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド 血友病治療のためのアデノウイルスベクター
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US7348014B2 (en) * 2000-04-14 2008-03-25 Transgene, S.A. Poxvirus with targeted infection specificity
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
EP2044948B1 (en) * 2002-08-12 2013-10-30 Jennerex Biotherapeutics ULC Vaccinia viruses for use in treating cancer
CA2494379C (en) 2002-09-05 2012-11-06 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
WO2005007857A1 (en) 2003-07-21 2005-01-27 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
EP2143788A1 (en) 2003-07-22 2010-01-13 Vivalis Production of poxviruses with duck cell lines
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US7951576B2 (en) * 2004-11-05 2011-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for preparing cells and viruses
DK2029756T3 (en) * 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS

Also Published As

Publication number Publication date
EP2530161A2 (en) 2012-12-05
HUE030533T2 (hu) 2017-05-29
US8415133B2 (en) 2013-04-09
RU2013119416A (ru) 2014-11-10
MX348525B (es) 2017-06-16
EP2029756B1 (en) 2016-11-09
US20120276614A1 (en) 2012-11-01
KR20090026295A (ko) 2009-03-12
CR10528A (es) 2009-05-14
MA30580B1 (fr) 2009-07-01
RU2013119415A (ru) 2014-11-10
US9295702B2 (en) 2016-03-29
EP2029756A1 (en) 2009-03-04
CA2656259C (en) 2013-03-19
IL194978A (en) 2016-04-21
US20100008953A1 (en) 2010-01-14
US20150110746A1 (en) 2015-04-23
BRPI0712158A2 (pt) 2012-01-17
HK1125405A1 (zh) 2009-08-07
NO20084855L (no) 2009-01-20
CA2656259A1 (en) 2007-12-27
BRPI0712158B1 (pt) 2019-12-10
US20120093780A1 (en) 2012-04-19
AU2007263280A1 (en) 2007-12-27
AU2007263280B2 (en) 2012-09-13
BRPI0712158B8 (pt) 2021-05-25
RU2581910C2 (ru) 2016-04-20
CN101460627B (zh) 2012-09-05
MX2008015166A (es) 2009-02-25
ES2611975T3 (es) 2017-05-11
WO2007147528A1 (en) 2007-12-27
NZ573437A (en) 2012-02-24
JP2009540806A (ja) 2009-11-26
ZA200810658B (en) 2009-12-30
RU2489486C2 (ru) 2013-08-10
CN101460627A (zh) 2009-06-17
US20130084620A1 (en) 2013-04-04
ES2671230T3 (es) 2018-06-05
HUE037866T2 (hu) 2018-09-28
DK2530161T3 (en) 2018-06-06
EP2530161A3 (en) 2013-11-06
US8058049B2 (en) 2011-11-15
JP5456464B2 (ja) 2014-03-26
US8415134B1 (en) 2013-04-09
RU2551982C2 (ru) 2015-06-10
EP2530161B1 (en) 2018-03-28
US8945581B2 (en) 2015-02-03
IL194978A0 (en) 2011-08-01
DK2029756T3 (en) 2017-02-13
KR101082296B1 (ko) 2011-11-09
RU2009101382A (ru) 2010-07-27

Similar Documents

Publication Publication Date Title
CO6141479A2 (es) Proceso para producir poxvirus y composiciones de poxvirus
CY1121159T1 (el) Μη-ενσωματουμενοι λεντiϊικοι φορεις
Schmid et al. AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
NO20052149L (no) Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.
CY1114598T1 (el) Μεθοδος για την ενισχυση ενος ιου φυσαλιδωδους νοσου υπο συνθηκες ελευθερες ορου
AR071220A1 (es) Astrovirus aviario depositado bajo el nuero cncm i-3895
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
NO20073737L (no) Hjelp for influensavirus
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
RU2011148791A (ru) Иммортализованные линии клеток птиц и их применение
DK1939281T4 (da) Immortaliserede andecellelinjer til virusproduktion
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
ES2570665T3 (es) Factor de permisividad celular para virus, y usos del mismo
CN1398297A (zh) 重组黄病毒及其用途
EA201071086A1 (ru) Усовершенствованный способ получения вакцинных антигенов вируса гриппа
AR101468A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
ES2561483T3 (es) Antígenos mutantes de GAS57 y anticuerpos de GAS57
AR057225A1 (es) Vacunas marcadas contra el virus de la diarrea virica bovina
MX2020013961A (es) Mutantes de hemaglutinina del virus de la influenza.
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
ATE313641T1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
US10280404B2 (en) Optimized HCV full-length infectious cell culture systems and applications thereof